Shusterman et al. described that the treatment of anti-GD2 antibody (hu14.18-IL2) with GM-CSF and isotretinoin for recurrent or refractory neuroblastoma was in progress in a phase 2 clinical study (ClinicalTrials.gov NCT01334515). This evidence concerns the gene IL2 and neuroblastoma.